A recent publication by Tantawy and colleagues (2023) investigates the unexpected connection between proteasome inhibitor, Carfilzomib (CFZ) and cardiovascular adverse events https://t.co/ws2nXEGyOO Read our summary of the paper below. https://t.co/UlTsnQ
429 followers
671 followers
Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma https://t.co/PA6CF3vYkW https://t.co/XipVVxcWHJ
2,794 followers
New Research: Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma: Background Proteasome inhibitor Carfilzomib (CFZ) is effective… #cardiovascular ht